Functionally, the constructs exhibited similar tumor killing after the first round, but a divergence emerged upon repeated exposure: hGM3/CD28H retained potent cytotoxicity through rounds two and three, while mGM3/CD28H showed a progressive decline across E:T ratios (Figure 4D). The gene discussed is TMIGD2; the disease is neoplasm.